```
     (FILE 'HOME' ENTERED AT 09:00:34 ON 30 MAR 2007)

     FILE 'REGISTRY' ENTERED AT 09:00:43 ON 30 MAR 2007
L1             STRUCTURE UPLOADED
L2           0 S L1 FAM SAM
L3           6 S L1 FAM FULL
L4             STRUCTURE UPLOADED
L5           0 S L4 FAM FULL

     FILE 'CAPLUS' ENTERED AT 09:03:01 ON 30 MAR 2007
L6          35 S L3
L7           5 S L6 AND PARKINSON?

     FILE 'REGISTRY' ENTERED AT 09:04:16 ON 30 MAR 2007
L8           1 S ROSUVASTATIN/CN

     FILE 'CAPLUS' ENTERED AT 09:04:53 ON 30 MAR 2007
L9         643 S L8
L10         12 S L9 AND PARKINSON?
L11         27 S (HMG-COA(W)REDUCTASE) AND PARKINSON?
L12          7 S L11 NOT PY>2003
L13        256 S ?STATIN AND PARKINSON?
L14         67 S L13 NOT PY>2002
L15          2 S L14 AND CHOLESTEROL
L16        306 S PARKINSON? AND (CHOLESTEROL OR HYPERLIPIDEM? OR HYPERCHOLESTE
L17         15 S L16 AND (HMG-COA)
L18          3 S L17 NOT PY>2003
```

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:00:43 ON 30 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3
DICTIONARY FILE UPDATES: 29 MAR 2007 HIGHEST RN 928707-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10525713verify.str





chain nodes :
13 14
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
10-13 11-14
ring bonds :
1-2 1-6 1-8 2-3 3-4 3-9 3-12 4-5 4-7 5-6 7-8 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 3-9 3-12 4-5 4-7 5-6 7-8 9-10 10-11 10-13 11-12

exact bonds :
11-14

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS

```
L1      STRUCTURE UPLOADED

=> s l1 fam sam
SAMPLE SEARCH INITIATED 09:01:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        4 TO ITERATE

100.0% PROCESSED         4 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            4 TO      200
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA FAM SAM L1

=> s l1 fam full
FULL SEARCH INITIATED 09:01:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      136 TO ITERATE

100.0% PROCESSED       136 ITERATIONS                                  6 ANSWERS
SEARCH TIME: 00.00.01

L3            6 SEA FAM FUL L1

=> d l3 scan

L3   6 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one (9CI)
MF   C9 H14 N2 O2
CI   COM
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3   6 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, (3R)- (9CI)
MF   C9 H14 N2 O2
CI   COM

Absolute stereochemistry.  Rotation (+).
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 6 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one, (3S)- (9CI)
MF C9 H14 N2 O2
CI COM

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Program Files\Stnexp\Queries\10525713verify2.str



ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
chain bonds :
15-17
ring bonds :
1-2 1-6 1-8 2-3 3-4 3-9 3-12 4-5 4-7 5-6 7-8 9-10 10-11 10-13 11-12
11-16 13-14 14-15 15-16 17-18 17-21 18-19 19-20 20-21
exact/norm bonds :
1-2 1-6 1-8 2-3 3-4 3-9 3-12 4-5 4-7 5-6 7-8 9-10 11-12 17-18 17-21
18-19 19-20 20-21
exact bonds :
15-17
normalized bonds :
10-11 10-13 11-16 13-14 14-15 15-16

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom

L4 STRUCTURE UPLOADED

=> s l4 fam full
FULL SEARCH INITIATED 09:02:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L5 0 SEA FAM FUL L4

=> d l4
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	136.30	136.51

FILE 'CAPLUS' ENTERED AT 09:03:01 ON 30 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Mar 2007 VOL 146 ISS 15
FILE LAST UPDATED: 29 Mar 2007 (20070329/ED)


```
=> s l3
L6          35 L3

=> s l6 and Parkinson?
         26400 PARKINSON?
L7           5 L6 AND PARKINSON?

=> d l7 1-5 ti

L7   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of spiro-oxazolidinone compounds as nicotinic acetylcholine
     receptor ligands

L7   ANSWER 2 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   A preparation of derivatives of oxazolidinone with affinity to the
     α7-nicotinic acetylcholine receptor

L7   ANSWER 3 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   α7-Nicotinic receptor agonists and statins in combination for the
     treatment of neurodegenerative diseases

L7   ANSWER 4 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and
     analogs as α-7 nicotinic receptor agonists

L7   ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and
     analogs as α-7 nicotinic receptor agonists


=> d l7 1-5 ti abs bib

L7   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Preparation of spiro-oxazolidinone compounds as nicotinic acetylcholine
     receptor ligands
GI
```



I



II

AB Title compds. I [Ar1, Ar2 = 5- or 6-membered aromatic or heteroarom. moiety having 0,1 or 2 nitrogen atoms, 0 or 1 oxygen atoms, and 0 or 1 sulfur atoms; wherein Ar1 is unsubstituted or has 1, 2 or 3 substituents selected from alkyl, alkenyl, alkynyl, etc. and Ar2 is unsubstituted or has 1, 2 or 3 substituents selected from -CONR1R2, -NR1COR2; R1, R2 = H, alkyl, or -NR1R2 in combination is -(CH2)jG(CH2)k-; G = bond, oxygen, sulfur, etc.; j = 2-4; k = 0-2] or stereoisomers, enantiomers, in vivo hydrolysable precursors and pharmaceutically acceptable salts thereof were prepared For example, Pd(PPh3)4 catalyzed coupling reaction of 4-(N,N-dimethylaminocarbonyl)phenylboronic acid with 2,5-dibromothiophene followed by reaction with (3S)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin]-2'-one afforded compound II. Compds. I are claimed useful as nicotinic acetylcholine receptor ligands for the treatment of anxiety, schizophrenia, etc. (no data).

AN 2006:608651 CAPLUS <<LOGINID::20070330>>
DN 145:83311

TI Preparation of spiro-oxazolidinone compounds as nicotinic acetylcholine receptor ligands

IN Chapdelaine, Marc; Chang, Hui-Fang; Herzog, Keith J.; Horchler, Carey; Phillips, Eifion
PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006065209	A1	20060622	WO 2005-SE1909	20051213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2004-636362P P 20041215
US 2005-643319P P 20050112

OS MARPAT 145:83311
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
TI A preparation of derivatives of oxazolidinone with affinity to the α7-nicotinic acetylcholine receptor
GI



I



II

AB The invention relates to a preparation of derivs. of oxazolidinone of formula Q-X-A-Y [wherein: Q is spiro(azabicyclooctanoxazolidinone) derivative; A is O, S, or NH, etc.; X is 5- or 6-membered heterocycle; Y is is 5- or 6-membered (hetero)aromatic ring] with affinity to the α7-nicotinic acetylcholine receptor. For instance, oxazolidinone derivative I was prepared via phenylation of II by phenylboronic acid. The compds. of the invention were screened in α7 nAChR subtype affinity assay and showed binding affinities (Ki) of less than 1000 nM.
AN 2005:58211 CAPLUS <<LOGINID::20070330>>
DN 142:155977
TI A preparation of derivatives of oxazolidinone with affinity to the α7-nicotinic acetylcholine receptor
IN Chang, Hui-Fang; Phillips, Eifion
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005005435	A1	20050120	WO 2004-GB2904	20040706
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004255920	A1	20050120	AU 2004-255920	20040706
	CA 2531510	A1	20050120	CA 2004-2531510	20040706

EP 1654264 A1 20060510 EP 2004-743249 20040706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR
CN 1829721 A 20060906 CN 2004-80021849 20040706
BR 2004012382 A 20060919 BR 2004-12382 20040706
US 2006154945 A1 20060713 US 2006-563271 20060104
NO 2006000612 A 20060406 NO 2006-612 20060208
PRAI US 2003-485523P P 20030708
WO 2004-GB2904 W 20040706
OS CASREACT 142:155977; MARPAT 142:155977
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
TI α7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
AB The invention discloses combinations of α7-nAChR agonists and statins, pharmaceutical compns. containing them, and methods of using them for the treatment or prophylaxis of neurol. degenerative diseases.
AN 2004:203672 CAPLUS <<LOGINID::20070330>>
DN 140:229466
TI α7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
IN Keith, Richard
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004019947	A1	20040311	WO 2003-SE1352	20030901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003256203	A1	20040319	AU 2003-256203	20030901
EP 1545537	A1	20050629	EP 2003-791540	20030901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505530	T	20060216	JP 2004-532517	20030901
US 2005256146	A1	20051117	US 2005-525783	20050228
PRAI SE 2002-2598	A	20020902		
WO 2003-SE1352	W	20030901		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists
AB The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A = (CH2)m; m = 2 or 3; T = (CH2)n; n = 1 or 2; Ar = (un)substituted aromatic heterocyclic ring, etc.] are prepared I are remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder, etc. Processes for preparing I are claimed in addnl. claims. In an in vitro test for affinity for the α-7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the Ki value of 4

nM. Formulations are given.

AN 2001:752491 CAPLUS <<LOGINID::20070330>>
Correction of: 2001:676769

DN 135:318499
Correction of: 135:242223

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists

IN Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi

PA Welfide Corporation, Japan

SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001066546	A1	20010913	WO 2001-JP1793	20010307

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2000-65545 A 20000309

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists

GI



I

AB The title compds. I [X = O, etc.; Y = O, etc.; R1 = H, alkyl, etc.; A = (CH2)m; m = 2 or 3; T = (CH2)n; n = 1 or 2; Ar = (un)substituted aromatic heterocyclic ring, etc.] are prepared I are remedies for dementia (e.g., Alzheimer disease), schizophrenia, cognition disorder, etc. Processes for preparing I are claimed in addnl. claims. In an in vitro test for affinity for the α-7 nicotinic receptors, (R)-3'-(5-bromo-2-thienyl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin-2'-one] showed the Ki value of 4 nM. Formulations are given.

AN 2001:676769 CAPLUS <<LOGINID::20070330>>

DN 135:242223

TI Preparation of spiro[azabicycloalkane-oxazolidinone] derivatives and analogs as α-7 nicotinic receptor agonists

IN Fujio, Masakazu; Hashimoto, Kenji; Katayama, Jiro; Numata, Atsushi

PA Welfide Corporation, Japan

SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DT Patent

LA Japanese

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
PI   WO 2001066546 A1          20010913   WO 2001-JP1793          20010307
     W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO,
         CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
         ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
         MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
         SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
         BY, KG, KZ, MD, RU, TJ, TM
     RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB,
         GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR
PRAI JP 2000-65545  20000309
OS   MARPAT 135:242223
RE.CNT  9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    18.80     155.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.90      -3.90

FILE 'REGISTRY' ENTERED AT 09:04:16 ON 30 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   29 MAR 2007  HIGHEST RN 928707-03-3
DICTIONARY FILE UPDATES:  29 MAR 2007  HIGHEST RN 928707-03-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s rosuvastatin/cn
L8            1 ROSUVASTATIN/CN

=> d l8


L8   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   287714-41-4  REGISTRY
ED   Entered STN:  29 Aug 2000
CN   6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-
     [methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, (3R,5S,6E)-
     (CA INDEX NAME)
OTHER NAMES:
CN   Rosuvastatin
CN   ZD 4522
```

FS STEREOSEARCH
MF C22 H28 F N3 O6 S
CI COM
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, MEDLINE, MRCK*, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

640 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
643 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.35	162.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

FILE 'CAPLUS' ENTERED AT 09:04:53 ON 30 MAR 2007

strictly prohibited.

FILE COVERS 1907 - 30 Mar 2007 VOL 146 ISS 15
FILE LAST UPDATED: 29 Mar 2007 (20070329/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l8
L9 643 L8

=> s l9 and Parkinson?
26400 PARKINSON?
L10 12 L9 AND PARKINSON?

=> d l10 1-12 ti

L10 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of multicyclic peptide derivatives as dipeptidyl peptidase-IV inhibitors

L10 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Compositions comprising β-blockers and methods for ameliorating cachexia

L10 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical composition containing HMG-CoA reductase inhibitor and glutathione

L10 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Method of reducing C-reactive protein using growth hormone secretagogues

L10 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of azabicyclic heterocycles as cannabinoid receptor modulators

L10 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Methods and compositions using a glutathione donor with other agents for the prevention and treatment of inflammatory diseases or conditions

L10 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of azabicyclic heterocycles as cannabinoid receptor modulators

L10 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Modulating cell activity by using an agent that reduces the level of cholesterol within a cell

L10 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrooxy derivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and anti-platelet activity

L10 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Statin compounds and their analogs for the treatment of diseases

L10 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI α7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases

L10 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Medicinal composition for mitigating blood lipid or lowering blood homocysteine containing HMG-CoA reductase inhibitors and pyridoxine compounds

=> d l10 5 6 8 9 10 11 12 ti abs bib

L10 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of azabicyclic heterocycles as cannabinoid receptor modulators
GI



I



II

AB The present application describes compds. I [R1, R2 = halo, CN, alkyl, etc.; R3 = H alkyl, alkenyl, cycloalkyl, etc.; R4 is absent when n is a double bond; R4 = H, alkyl, cycloalkyl, etc.; R5 = halo, (un)substituted OH, NH2, etc. when m is a single bond; R5 = O when m = a double bond; m, n = a single or double bond; when m is a single bond, n is a double bond; when m is a double bond, n is a single bond], pharmaceutical compns. comprising at least one compound I and optionally one or more addnl. therapeutic agents and methods of treatment using the compds. I both alone and in combination with one or more addnl. therapeutic agents. Over 40 compds. I were prepared E.g., a multi-step synthesis of II, starting from dichloromandelic anhydride, was given. The exemplified compds. I showed the CB-1 receptor binding Ki values in the range of 0.01 nM to 10000 nM.

AN 2005:612299 CAPLUS <<LOGINID::20070330>>
DN 143:133380
TI Preparation of azabicyclic heterocycles as cannabinoid receptor modulators
IN Gu, Guixue; Ewing, William R.; Mikkilineni, Amarendra B.; Pendri, Annapurna; Ellsworth, Bruce A.; Sher, Philip M.; Gerritz, Samuel; Sun, Chongqing; Murugesan, Natesan; Wu, Ximao
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005063762	A1	20050714	WO 2004-US42878	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004309368	A1	20050714	AU 2004-309368	20041217
CA 2550375	A1	20050714	CA 2004-2550375	20041217
US 2005171110	A1	20050804	US 2004-16198	20041217

```
     EP 1697371           A1    20060906    EP 2004-815007          20041217
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
            HR, IS, YU
     CN 1918164           A     20070221    CN 2004-80041904        20041217
     EP 1699796           A1    20060913    EP 2004-814691          20041220
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
            HR, IS, YU
     NO 2006002689        A     20060912    NO 2006-2689            20060612
     NO 2006002691        A     20060914    NO 2006-2691            20060612
PRAI US 2003-531451P      P     20031219
     US 2004-16198        A     20041217
     WO 2004-US42878      W     20041217
     WO 2004-US42542      W     20041220
OS   MARPAT 143:133380
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10  ANSWER 6 OF 12  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Methods and compositions using a glutathione donor with other agents for
     the prevention and treatment of inflammatory diseases or conditions
AB   The invention discloses methods and compns. for treating or preventing
     inflammatory diseases or conditions in a patient, comprising administering
     to the patient a therapeutically effective amount of a composition comprising a
     glutathione donor, 5-amino 4-imidazolecarboxamide ribotide (AICAR), an
     HMG-CoA reductase inhibitor, D-threo-1-phenyl-2-decanoylamino-3-morpholino-
     1-propanol HCl (D-PDMP), and/or 1,5-(butylimino)-1,5-dideoxy-D-glucitol
     (Miglustat), or derivs. thereof.
AN   2005:612106  CAPLUS <<LOGINID::20070330>>
DN   143:109792
TI   Methods and compositions using a glutathione donor with other agents for
     the prevention and treatment of inflammatory diseases or conditions
IN   Singh, Inderjit
PA   Musc Foundaton for Research Development, USA
SO   PCT Int. Appl., 106 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2005063275         A1    20050714    WO 2004-US43432         20041223
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
            RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
            MR, NE, SN, TD, TG
     AU 2004308966        A1    20050714    AU 2004-308966          20041223
     CA 2548313           A1    20050714    CA 2004-2548313         20041223
     EP 1711197           A1    20061018    EP 2004-817053          20041223
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
     CN 1897961           A     20070117    CN 2004-80038400        20041223
PRAI US 2003-531828P      P     20031223
     US 2004-559112P      P     20040402
     WO 2004-US43432      W     20041223
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
```

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
AB The invention discloses methods for modulating the activity of cells, and compns. useful in such methods. In particular, the invention relates to the use of an agent that reduces the level of cholesterol within a cell to modulate the activity of the cell, and to methods involving such use.
AN 2005:238842 CAPLUS <<LOGINID::20070330>>
DN 142:291452
TI Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
IN Allen, Janet Marjorie; Overington, John Paul
PA Inpharmatica Limited, UK
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005023305	A2	20050317	WO 2004-GB3875	20040910
	WO 2005023305	A3	20050616		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI GB 2003-21228 A 20030910

L10 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of nitrooxy derivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and anti-platelet activity
GI



I

AB Nitrooxy derivs. of therapeutic agents, such as RCO-X-Y-ONO2 [RCO = acyl residue of therapeutic agents, including statin acids, such as

fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin, ACE inhibitors, angiotensin II receptor antagonists, β-adrenergic blockers, calcium channel blockers, antithrombotics and aspirin; X = O, S, NR1; Y = linking group, such as, alkylene or phenylene alone or in combination; R1 = H, alkyl], with improved pharmacol. activity and enhanced tolerability were prepared for therapeutic use in treating and/or preventing several diseases, in particular coronary syndromes and neurodegenerative disorders and autoimmune disorders , as well as for reducing cholesterol levels. The vascular disorders for treatment include acute coronary syndromes, stroke, peripheral vascular diseases, disorders associated with endothelial dysfunction, peripheral ischemia, vascular complications in diabetic patients and atherosclerosis. The neurodegenerative diseases for treatment include Alzheimer's disease, Parkinson's disease and multiple sclerosis. Thus, ester I was prepared via an esterification reaction of pravastatin sodium with 1,4-dibromobutane n DMF and subsequent treatment of the resulting 4-bromobutanyl pravastatin ester with silver nitrate in MeCN. The prepared nitrooxy statin derivs. were assayed for their ability to induce vasorelaxation, for their effect in vitro on inflammatory pathways, for activity on peripheral vascular disease, for effect on leukocyte adhesion, for antithrombotic activity, for anti-platelet activity, and for inhibition of tissue factor expression.

AN 2004:1059168 CAPLUS <<LOGINID::20070330>>
DN 142:38061

TI Preparation of nitrooxy derivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and anti-platelet activity

IN Benedini, Francesca; Ongini, Ennio; Del Soldato, Piero
PA Nicox S. A., Fr.

SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004105754	A1	20041209	WO 2004-EP50897	20040524
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005165084	A1	20050728	US 2004-849561	20040520
	US 7166638	B2	20070123		
	AU 2004243443	A1	20041209	AU 2004-243443	20040524
	CA 2527168	A1	20041209	CA 2004-2527168	20040524
	EP 1626716	A1	20060222	EP 2004-741636	20040524
	EP 1626716	B1	20070207		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004010049	A	20060425	BR 2004-10049	20040524
	CN 1794987	A	20060628	CN 2004-80014498	20040524
	AT 353214	T	20070215	AT 2004-741636	20040524
	NO 2005006152	A	20051223	NO 2005-6152	20051223
	US 2007072942	A1	20070329	US 2006-590770	20061101
PRAI	EP 2003-101530	A	20030527		
	US 2004-849561	A3	20040520		
	WO 2004-EP50897	W	20040524		

OS MARPAT 142:38061
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Statin compounds and their analogs for the treatment of diseases
AB The invention provides derivs. of statin compds., preferably with reduced, or inappreciable, inhibitory activity against HMG-CoA reductase as well as compns. comprising such compds. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects. Kits comprising the non-statin compds. of the invention are also provided.
AN 2004:1037065 CAPLUS <<LOGINID::20070330>>
DN 142:737
TI Statin compounds and their analogs for the treatment of diseases
IN Lockhart, David J.; Patel, Hitesh K.; Milanov, Zdravko V.; Mehta, Shamal Anil
PA Ambit Biosciences Corporation, USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103960	A2	20041202	WO 2004-US15543	20040517
	WO 2004103960	A3	20050127		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004242673	A1	20041202	US 2004-847897	20040517
	US 2004248972	A1	20041209	US 2004-848515	20040517
	US 2004248957	A1	20041209	US 2004-848521	20040517
PRAI	US 2003-471425P	P	20030516		
	US 2003-480289P	P	20030620		
	US 2003-480475P	P	20030620		
	US 2003-488172P	P	20030716		
	US 2003-488178P	P	20030716		
	US 2003-516610P	P	20031030		
	US 2003-516616P	P	20031030		
	US 2003-516651P	P	20031030		

L10 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI α7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
AB The invention discloses combinations of α7-nAChR agonists and statins, pharmaceutical compns. containing them, and methods of using them for the treatment or prophylaxis of neurol. degenerative diseases.
AN 2004:203672 CAPLUS <<LOGINID::20070330>>
DN 140:229466
TI α7-Nicotinic receptor agonists and statins in combination for the treatment of neurodegenerative diseases
IN Keith, Richard
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004019947	A1	20040311	WO 2003-SE1352	20030901
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003256203	A1	20040319	AU 2003-256203	20030901
	EP 1545537	A1	20050629	EP 2003-791540	20030901
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505530	T	20060216	JP 2004-532517	20030901
	US 2005256146	A1	20051117	US 2005-525783	20050228
PRAI	SE 2002-2598	A	20020902		
	WO 2003-SE1352	W	20030901		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Medicinal composition for mitigating blood lipid or lowering blood homocysteine containing HMG-CoA reductase inhibitors and pyridoxine compounds
AB Disclosed is a safe drug for mitigating blood lipid and for reducing the amount of blood homocysteine. It is a medicinal composition containing an HMG-CoA
reductase inhibitor and a pyridoxine compound The effect of simvastatin in combination with pyridoxine hydrochloride on blood cholesterol in beagle dog was examined A tablet containing simvastatin 1.67, pyridoxine hydrochloride
16.7, and other ingredients q.s. to 200 mg was prepared
AN 2004:60308 CAPLUS <<LOGINID::20070330>>
DN 140:99668
TI Medicinal composition for mitigating blood lipid or lowering blood homocysteine containing HMG-CoA reductase inhibitors and pyridoxine compounds
IN Kondo, Tatsuhito; Takagi, Ikuo; Nakayama, Masato; Torizumi, Yasuhiro
PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004006919	A1	20040122	WO 2003-JP8674	20030708
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

```
     CA 2492781           A1    20040122    CA 2003-2492781        20030708
     AU 2003281176        A1    20040202    AU 2003-281176         20030708
     CN 1681499           A     20051012    CN 2003-821641         20030708
     JP 2004189716        A     20040708    JP 2003-272681         20030710
     US 2005182106        A1    20050818    US 2005-31105          20050107
PRAI JP 2002-202121       A     20020711
     JP 2002-343586       A     20021127
     WO 2003-JP8674       W     20030708
RE.CNT  13    THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s (HMG-CoA(w)reductase) and Parkinson?
         10821 HMG
         45645 COA
          7081 HMG-COA
                 (HMG(W)COA)
         90801 REDUCTASE
          6562 HMG-COA(W)REDUCTASE
         26400 PARKINSON?
L11         27 (HMG-COA(W)REDUCTASE) AND PARKINSON?

=> s l11 not py>2003
       4038758 PY>2003
L12          7 L11 NOT PY>2003

=> d l12 1-7 ti

L12  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Methods and compositions for enhancing pharmaceutical treatments

L12  ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Drug evaluation operating principles

L12  ANSWER 3 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Hypothalamic digoxin related membrane Na+-K+ ATPase inhibition and
     familial basal ganglia calcification

L12  ANSWER 4 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Membrane Na+ K+ ATPase inhibition related dyslipidemia and insulin
     resistance in neuropsychiatric disorders

L12  ANSWER 5 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Alteration in glycoconjugate metabolism in CNS disorders - role of
     isoprenoid pathway

L12  ANSWER 6 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Isoprenoid pathway and free radical generation and damage in
     neuropsychiatric disorders

L12  ANSWER 7 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Decreased cholesterol biosynthesis in fibroblasts from patients with
     Parkinson disease


=> d l12 1 2 4 5 6 7 ti abs bib

L12  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Methods and compositions for enhancing pharmaceutical treatments
AB   Improved methods are provided for therapeutic and/or preventative
     treatment to a mammal in which the mammal is protected against the
     toxicity of active pharmaceutical agents that (i) bind to or are
     substrates for P-gp, (ii) are taxane analogs, and/or (iii) are inhibitors
     of tubulin disassembly.  Addnl. provided are compns. and methods useful
```

for treating cell proliferative disorders. Further provided are methods of increasing the bioavailability of therapeutic and/or preventative treatments in a mammal. Particular embodiments are directed to increasing such bioavailability across the blood-brain barrier.

AN 2002:778718 CAPLUS <<LOGINID::20070330>>
DN 137:289046
TI Methods and compositions for enhancing pharmaceutical treatments
IN Newman, Michael J.; Dixon, William Ross
PA USA
SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 684,293.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002147197	A1	20021010	US 2002-104549	20020320
PRAI	US 1999-158322P	P	19991008		
	US 2000-684293	A2	20001006		

OS MARPAT 137:289046

L12 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Drug evaluation operating principles
AB The present invention relates to methods for determining whether a drug candidate should be advanced from discovery through evaluation to development and marketing. In one embodiment of the present invention, the drug development methods utilize a team decision-making format wherein scientific staff, and regulatory, financial, and marketing personnel may contribute to the evaluation of a new drug compound In another embodiment of the methods of the present invention, decisions concerning the future of a potential drug may be made at earlier designated timepoints in the evaluation process, and these decisions may be made based on criteria such as preclin. pharmacol. and toxicol. data. In a further embodiment of the present invention, the potential new drug may be assigned a risk characterization, such as a color code, which defines the extent and duration of the evaluation process.

AN 2002:488167 CAPLUS <<LOGINID::20070330>>
DN 137:57524
TI Drug evaluation operating principles
IN Ernest, Michael; Slate, Doris L.
PA USA
SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002081750	A1	20020627	US 2001-956094	20010920
PRAI	US 2000-257166P	P	20001222		

L12 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Membrane Na+ K+ ATPase inhibition related dyslipidemia and insulin resistance in neuropsychiatric disorders
AB There are several reports in literature implicating cholesterol metabolism in the pathogenesis of neuronal degenerations, oncogenesis, functional neuropsychiatric disorders and multiple sclerosis. Biosynthesis of cholesterol takes place by the isoprenoid pathway, which also produces digoxin, an inhibitor of membrane Na+-K+ ATPase. Inhibition of this enzyme results in intracellular Mg++ deficiency which can influence cholesterol metabolism Digoxin also influences transport of tryptophan and tyrosine which are precursors of various neurotransmitters. Alterations in digoxin, membrane Na+-K+ ATPase and also in neurotransmitters have been reported in the disorders mentioned above. In view of this, serum lipid

profile, activity of plasma HMG CoA reductase (the major rate limiting step in the isoprenoid pathway), RBC membrane Na+-K+ ATPase activity, serum Mg++ concentration, concentration of digoxin and concentration of serum neurotransmitters were studied in some neuropsychiatric disorders. The serum serotonin level was increased while that of serum dopamine and noradrenaline was reduced. Serum digoxin levels were high and RBC membrane sodium-potassium ATPase activity and serum magnesium were reduced. There was a reduction in HDL cholesterol and increase in plasma triglycerides (pattern similar to insulin resistance and syndrome X) in most of the disorders studied. The HMG CoA reductase activity was high, the serum total cholesterol was increased while RBC membrane cholesterol was reduced in most of the cases. The significance of increased digoxin with consequent inhibition of membrane Na+-K+ ATPase in relation to changes in cholesterol metabolism and insulin resistance type of dyslipidemia is discussed in this paper.

AN 2001:683793 CAPLUS <<LOGINID::20070330>>
DN 136:214833
TI Membrane Na+ K+ ATPase inhibition related dyslipidemia and insulin resistance in neuropsychiatric disorders
AU Kumar, A. Ravi; Kurup, P. A.
CS Department of Neurology, Medical College Hospital, Trivandrum, 695 011, India
SO Indian Journal of Physiology and Pharmacology (2001), 45(3), 296-304
CODEN: IJPPAZ; ISSN: 0019-5499
PB Association of Physiologists and Pharmacologists of India
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Alteration in glycoconjugate metabolism in CNS disorders - role of isoprenoid pathway
AB The isoprenoid pathway which is upregulated in neuropsychiatric disorders produces 2 metabolites which can regulate glycoconjugate metabolism - dolichol (required for N-glycosylation) and digoxin (endogenous membrane Na-K ATPase inhibitor producing magnesium depletion). It is known that Mg++ deficiency can influence glycoconjugate metabolism The results showed an increase in the concentration of blood serum total glycosaminoglycan (GAG), glycolipids and carbohydrate component of glycoproteins and a decrease in the total GAG and carbohydrate component of glycoproteins in the red blood cell (RBC) membrane suggesting their reduced incorporation into the membrane. The pattern of change in individual GAG in the serum was different, however heparan sulfate (HS) and chondroitin sulfate (ChS) increased in most of the disorders studied. The activity of GAG degrading enzymes and glycohydrolases showed significant increase in the serum in all the groups suggesting reduced lysosomal stability consequent to defective lysosomal membrane formation. The importance of altered glycoconjugate metabolism in the pathogenesis of multiple sclerosis, Parkinson's disease, schizophrenia, epilepsy and CNS gliomas is stressed.
AN 2001:363560 CAPLUS <<LOGINID::20070330>>
DN 135:342594
TI Alteration in glycoconjugate metabolism in CNS disorders - role of isoprenoid pathway
AU Kurup, Ravi Kumar Achutha; Devi, Deepa; Augustine, Jyothi; Kurup, Parameswara Achutha
CS Department of Neurology, Medical College Hospital, Trivandrum, 695011, India
SO Neuroscience Research Communications (2001), 28(2), 95-106
CODEN: NRCOEE; ISSN: 0893-6609
PB Wiley-Liss, Inc.
DT Journal

LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders
AB Two substances which are products of the isoprenoid pathway, can participate in lipid peroxidn. 1 Is digoxin, which by inhibiting membrane Na+-K+ ATPase, causes increase in intracellular Ca2+ and depletion of intracellular Mg2+, both effects contributing to increase in lipid peroxidn. Ubiquinone, another products of the pathway is a powerful membrane antioxidant and its deficiency can also result in defective electron transport and generation of reactive O species. In view of this and also in the light of some preliminary reports on alteration in lipid peroxidn. in neuropsychiatric disorders, a study was undertaken on the following aspects in some of these disorders (primary generalized epilepsy, schizophrenia, multiple sclerosis, Parkinson's disease and CNS glioma) - (1) concentration of digoxin, ubiquinone, activity of HMG CoA reductase and RBC membrane Na+-K+ ATPase, (2) activity of enzymes involved in free radical scavenging, (3) parameters of lipid peroxidn., and (4) antioxidant status. The result obtained indicates an increase in the concentration of digoxin and activity of HMG CoA reductase, decrease in ubiquinone levels and in the activity of membrane Na+-K+ ATPase. There is increased lipid peroxidn. as evidenced from the increase in the concentration of MDA, conjugated dienes, hydroperoxides and NO with decreased antioxidant protection as indicated by decrease in ubiquinone, vit. E and reduced glutathione in schizophrenia, Parkinson's disease and CNS glioma. The activity of enzymes involved in free radical scavenging like SOD, catalase, glutathione peroxidase and glutathione reductase is decreased in the above diseases. However, there is no evidence of any increase in lipid peroxidn. in epilepsy or MS. The role of increased operation of the isoprenoid pathway as evidenced by alteration in the concentration of digoxin and ubiquinone in the generation of free radicals and protection against them in these disorders is discussed.
AN 2000:450831 CAPLUS <<LOGINID::20070330>>
DN 133:320518
TI Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders
AU Ravikumar, A.; Arun, P.; Devi, K. V. Deepa; Augustine, J.; Kurup, P. A.
CS Department of Neurology, Medical College, Thiruvananthapuram, 695 011, India
SO Indian Journal of Experimental Biology (2000), 38(5), 438-446
CODEN: IJEBA6; ISSN: 0019-5189
PB National Institute of Science Communication, CSIR
DT Journal
LA English
RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease
AB The underlying cause of cellular degeneration in the substantia nigra of patients with Parkinson disease has not been clearly established. Metabolic abnormalities may be detected in peripheral non-neuronal cells, such as skin fibroblasts of the patients. A remarkably reduced cholesterol biosynthetic capability was found in fibroblasts from patients with Parkinson disease. The [14C]acetate incorporation into cholesterol was 27.8% of that observed in normal fibroblasts, and the reduced cholesterol synthesis was confirmed by measuring the activity of the rate-limiting enzyme HMGCoA reductase which averaged 6.64 nmol/h/mg protein in the patient fibroblasts compared to

14.70 nmol/h/mg protein in the control fibroblasts. The cholesterol esterification activity, determined as cholesteryl oleate formed from [14C]oleate, of the fibroblasts from Parkinson patients was reduced by 43%. Two hypotheses link the findings with the current exptl. evidences for both increased lipid peroxidn. and defective mitochondrial respiratory chain complex I activity in cells from Parkinson patients. Considering that the decreased cholesterol biosynthesis has been detected in all Parkinson cell lines thus far investigated, this may be a hallmark of the disease.

AN 1993:252610 CAPLUS <<LOGINID::20070330>>
DN 118:252610
TI Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease
AU Musanti, Roberto; Parati, Eugenio; Lamperti, Elena; Ghiselli, Giancarlo
CS Res. Inst., Farmitalia Carlo Erba, Milan, Italy
SO Biochemical Medicine and Metabolic Biology (1993), 49(2), 133-42
CODEN: BMMBES; ISSN: 0885-4505
DT Journal
LA English

=> s ?statin and Parkinson?
61805 ?STATIN
26400 PARKINSON?
L13 256 ?STATIN AND PARKINSON?

=> s l13 not py>2002
5089233 PY>2002
L14 67 L13 NOT PY>2002

=> s l14 and cholesterol
171998 CHOLESTEROL
L15 2 L14 AND CHOLESTEROL

=> d l15 1-2 ti

L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Review: mitochondrial medicine - molecular pathology of defective oxidative phosphorylation

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Oral pharmaceutical controlled-release liquid suspension containing oils and polymers and antioxidants

=> d l15 1-2 ti abs bib

L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Review: mitochondrial medicine - molecular pathology of defective oxidative phosphorylation
AB A review with 322 refs. Different tissues display distinct sensitivities to defective mitochondrial oxidative phosphorylation (OXPHOS). Tissues highly dependent on O such as the cardiac muscle, skeletal and smooth muscle, the central and peripheral nervous system, the kidney, and the insulin-producing pancreatic β-cell are especially susceptible to defective OXPHOS. There is evidence that defective OXPHOS plays an important role in atherogenesis, in the pathogenesis of Alzheimer's disease, Parkinson's disease, diabetes, and aging. Defective OXPHOS may be caused by abnormal mitochondrial biosynthesis due to inherited or acquired mutations in the nuclear (n) or mitochondrial (mt) DNA. For instance, the presence of a mutation of the mtDNA in the pancreatic β-cell impairs ATP (ATP) generation and insulin synthesis. The nuclear genome controls mitochondrial biosynthesis, but mtDNA has a much higher mutation rate than nDNA because it lacks histones and is exposed to the radical O species

(ROS) generated by the electron transport chain, and the mtDNA repair system is limited. Defective OXPHOS may be caused by insufficient fuel supply, by defective electron transport chain enzymes (Complexes I-IV), lack of the electron carrier coenzyme Q10, lack of oxygen due to ischemia or anemia, or excessive membrane leakage, resulting in insufficient mitochondrial inner membrane potential for ATP synthesis by the F0F1-ATPase. Human tissues can counteract OXPHOS defects by stimulating mitochondrial biosynthesis; however, above a certain threshold the lack of ATP causes cell death. Many agents affect OXPHOS. Several nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit or uncouple OXPHOS and induce the 'topical' phase of gastrointestinal ulcer formation. Uncoupled mitochondria reduce cell viability. The Helicobacter pylori induces uncoupling. The uncoupling that opens the membrane pores can activate apoptosis. Cholic acid in exptl. atherogenic diets inhibits Complex IV, cocaine inhibits Complex I, the poliovirus inhibits Complex II, ceramide inhibits Complex III, azide, cyanide, chloroform, and methamphetamine inhibit Complex IV. EtOH abuse and antiviral nucleoside analog therapy inhibit mtDNA replication. By contrast, melatonin stimulates Complexes I and IV and Ginkgo biloba stimulates Complexes I and III. Oral Q10 supplementation is effective in treating cardiomyopathies and in restoring plasma levels reduced by the statin type of cholesterol -lowering drugs.

AN 2001:79969 CAPLUS <<LOGINID::20070330>>
DN 135:44211
TI Review: mitochondrial medicine - molecular pathology of defective oxidative phosphorylation
AU Fosslien, Egil
CS Department of Pathology, University of Illinois, Chicago, IL, 60612, USA
SO Annals of Clinical and Laboratory Science (2001), 31(1), 25-67
CODEN: ACLSCP; ISSN: 0091-7370
PB Association of Clinical Scientists
DT Journal; General Review
LA English
RE.CNT 322 THERE ARE 322 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Oral pharmaceutical controlled-release liquid suspension containing oils and polymers and antioxidants
AB A controlled-release oral formulation for use with a variety of drugs, e.g. anti-Parkinsonian, cardiovascular and anti-epileptic drugs are formed in liquid suspension form. The ingredients in the suspension are water, and edible oil and a stabilizer for the liquid suspension, at least one pharmaceutically active ingredient, at least two water soluble biodegradable polymers, and optionally with at least one antioxidant to prevent degradation and oxidation of the pharmaceutically active ingredients.
A
typical tsp dose of anti-Parkinson liquid suspension contains 15-150 mg carbidopa, 50-1500 mg levodopa, 100-300 mg of a combination of polyvinyl alc. and polysucrose, 10-50 mg oil, 5-15 mg antioxidant, e.g. vitamin E, 5-20 mg stabilizer, 10-15 mg colorants, 10-15 mg natural flavoring agents and 5 mL water.
AN 1996:65002 CAPLUS <<LOGINID::20070330>>
DN 124:127144
TI Oral pharmaceutical controlled-release liquid suspension containing oils and polymers and antioxidants
IN Modi, Pankaj
PA Can.
SO Can. Pat. Appl., 18 pp.
CODEN: CPXXEB
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     ---------------      ----   --------    --------------------   --------
PI   CA 2143070           A1     19950823    CA 1995-2143070        19950221
     CA 2143070           C      20011218
PRAI US 1994-199933       A      19940222


=> s Parkinson? and (cholesterol or hyperlipidem? or hypercholesterolem?)
         26400 PARKINSON?
        171998 CHOLESTEROL
         13636 HYPERLIPIDEM?
         16403 HYPERCHOLESTEROLEM?
L16        306 PARKINSON? AND (CHOLESTEROL OR HYPERLIPIDEM? OR HYPERCHOLESTEROL
               EM?)

=> s l16 and (HMG-CoA)
         10821 HMG
         45645 COA
          7081 HMG-COA
                 (HMG(W)COA)
L17         15 L16 AND (HMG-COA)

=> s l17 not py>2003
       4038758 PY>2003
L18           3 L17 NOT PY>2003

=> d l18 1-3 ti

L18  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Hypothalamic digoxin related membrane Na+-K+ ATPase inhibition and
     familial basal ganglia calcification

L18  ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Membrane Na+ K+ ATPase inhibition related dyslipidemia and insulin
     resistance in neuropsychiatric disorders

L18  ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Decreased cholesterol biosynthesis in fibroblasts from patients
     with Parkinson disease
```